Copyright
©The Author(s) 2015.
World J Hepatol. Dec 8, 2015; 7(28): 2841-2848
Published online Dec 8, 2015. doi: 10.4254/wjh.v7.i28.2841
Published online Dec 8, 2015. doi: 10.4254/wjh.v7.i28.2841
Unmatched patients | Standardized | Propensity score matched patients | Standardized | |||||
Telaprevir | Simeprevir | P value | difference | Telaprevir | Simeprevir | P value | difference | |
No. of patients | n = 159 | n = 147 | n = 104 | n = 104 | ||||
Age (yr) | 60 (51.0-65.0) | 63 (54.5-70.0) | 0.002 | 0.348 | 61.5 (53.0-65.8) | 60.5 (52.0-67.0) | NS | 0.0154 |
Gender (male/female) | 77/82 | 67/80 | NS | 0.057 | 45/59 | 49/55 | NS | 0.0773 |
Body mass index (kg/m2) | 23.9 (21.7-25.7) | 23.2 (21.1-25.0) | NS | 0.202 | 23.6 (21.1-25.3) | 23.4 (21.2-25.2) | NS | 0.0747 |
Laboratory data | ||||||||
Level of viremia (log IU/mL) | 6.7 (6.3-7.0) | 6.8 (6.3-7.2) | NS | 0.210 | 6.7 (6.3-7.0) | 6.6 (6.2-7.1) | NS | 0.0158 |
Leukocyte count (/mm3) | 5060 (4200-5800) | 4920 (4100-5800) | NS | 0.094 | 5000 (4200-5700) | 5020 (4150-5800) | NS | 0.0272 |
Hemoglobin (g/dL) | 14.1 (13.1-15.0) | 13.8 (12.9-14.7) | NS | 0.175 | 14 (13.0-14.8) | 13.9 (12.9-15.0) | NS | 0.0264 |
Platelet count (× 104/mm3) | 15 (12.5-19.8) | 15.1 (11.7-20.1) | NS | 0.053 | 15 (12.9-20.0) | 15.1 (11.8-20.1) | NS | 0.0032 |
SNP of IL28B (TT/non-TT/unknown) | 99/34/26 | 89/43/15 | NS | 0.155 | 74/30 | 73/31 | NS | 0.0211 |
Other data | ||||||||
Prior treatment response relapse/other | 43/30 | 31/32 | NS | 0.196 | 31/22 | 23/20 | NS | 0.100 |
Parameters | Telaprevir | Simeprevir | ||||
SVR | Non-SVR | P value | SVR | Non-SVR | P value | |
Unmatched patients | ||||||
Univariate analysis | n = 126 | n = 33 | n = 102 | n = 45 | ||
Age (yr) | 58.0 (51.0-65.0) | 62.0 (59.6-65.5) | NS | 61.0 (52.8-67.3) | 66.0 (56.5-71.0) | 0.016 |
Gender (male/female) | 62/64 | 15/18 | NS | 48/54 | 19/26 | NS |
Body mass index (kg/m2) | 23.8 (21.7-25.7) | 24.6 (21.7-26.0) | NS | 23.2 (21.0-25.1) | 23.5 (21.3-26.0) | NS |
Level of viremia (log IU/mL) | 6.7 (6.3-7.0) | 6.6 (6.3-7.0) | NS | 6.8 (6.2-7.1) | 6.9 (6.4-7.3) | NS |
Leukocyte count (/mm3) | 5100 (4200-5700) | 5100 (4400-6600) | NS | 5000 (4300-5800) | 4800 (3800-5800) | NS |
Hemoglobin (g/dL) | 14.1 (13.2-15.1) | 14.1 (12.8-14.8) | NS | 13.9 (13.1-14.7) | 13.7 (12.7-14.8) | NS |
Platelet count (× 104/mm3) | 15.0 (12.8-19.8) | 15.0 (12.5-20.1) | NS | 15.3 (11.9-20.5) | 15.0 (11.1-18.3) | NS |
SNP of IL28B (TT/non-TT) | 84/19 | 15/15 | < 0.001 | 72/19 | 17/24 | < 0.001 |
Multivariate analysis | Odds ratio (95%CI) | Odds ratio (95%CI) | ||||
SNP of IL28B (TT/non-TT) | 4.316 (1.804-10.327) | 0.001 | 8.598 (3.388-21.817) | < 0.001 | ||
Age (yr) | 0.933 (0.889-0.980) | 0.006 | ||||
Level of viremia (log IU/mL) | 0.335 (0.157-0.715) | 0.005 | ||||
Propensity score matched patients | ||||||
Univariate analysis | n = 77 | n = 27 | n = 76 | n = 28 | ||
Age (yr) | 60.0 (52.5-66.5) | 64.0 (60.0-65.0) | NS | 59.0 (51.0-66.0) | 65.0 (56.0-71.0) | 0.021 |
Gender (male/female) | 33/44 | 12/15 | NS | 37/39 | 12/16 | NS |
Body mass index (kg/m2) | 23.1 (20.6-25.0) | 24.0 (21.4-26.6) | NS | 23.2 (21.3-25.1) | 23.6 (21.1-26.1) | NS |
Level of viremia (log IU/mL) | 6.7 (6.3-7.0) | 6.7 (6.4-6.9) | NS | 6.7 (6.1-7.0) | 6.6 (6.3-7.2) | NS |
Leukocyte count (/mm3) | 5000 (4100-5700) | 5100 (4400-6700) | NS | 5100 (4400-5900) | 4600 (3500-5700) | NS |
Hemoglobin (g/dL) | 14.0 (13.1-14.8) | 13.9 (13.0-14.9) | NS | 14.0 (12.9-15.0) | 13.8 (12.9-14.7) | NS |
Platelet count (× 104/mm3) | 15.0 (12.3-19.7) | 15.4 (12.9-20.3) | NS | 15.1 (11.9-20.4) | 15.0 (11.0-17.2) | NS |
SNP of IL28B (TT/non-TT) | 61/16 | 13/14 | 0.002 | 61/15 | 12/16 | < 0.001 |
Multivariate analysis | Odds ratio (95%CI) | Odds ratio (95%CI) | ||||
SNP of IL28B (TT/non-TT) | 7.739 (2.111-28.375) | 0.002 | 8.594 (2.777-26.598) | < 0.001 |
-
Citation: Fujii H, Nishimura T, Umemura A, Nishikawa T, Yamaguchi K, Moriguchi M, Sumida Y, Mitsuyoshi H, Yokomizo C, Tanaka S, Ishikawa H, Nishioji K, Kimura H, Takami S, Nagao Y, Takeuchi T, Shima T, Sawa Y, Minami M, Yasui K, Itoh Y. Comparison of peg-interferon, ribavirin plus telaprevir
vs simeprevir by propensity score matching. World J Hepatol 2015; 7(28): 2841-2848 - URL: https://www.wjgnet.com/1948-5182/full/v7/i28/2841.htm
- DOI: https://dx.doi.org/10.4254/wjh.v7.i28.2841